Pfizer Urges 3rd Circ. Not To Revive Lipitor Antitrust Row
Pfizer and Ranbaxy urged the Third Circuit on Monday to either uphold a New Jersey federal court's dismissal of claims that it paid Ranbaxy to postpone releasing a generic of the...To view the full article, register now.
Already a subscriber? Click here to view full article